Skip to main content

2022 CTOS Annual Meeting Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Vivek Kadambi, PhD

IDRx, Inc

Poster(s):

(P 316) FIRST-IN-HUMAN PHASE 1/1B STUDY OF IDRX-42, A NOVEL ORAL TYROSINE KINASE KIT INHIBITOR, IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS